Expert Opin Drug Deliv. 2007 Mar;4(2):149-64.

Gadolinium(III)-based blood-pool contrast agents for magnetic resonance imaging: status and clinical potential.

Source

Georgia Tech and Emory University, Wallace H. Coulter Department of Biomedical Engineering, Emory University School of Medicine, Atlanta, USA.

Abstract

Blood-pool MRI contrast agents have enormous potential to aid sensitive magnetic resonance detection and yield definitive diagnostic data of cancer and diseases of the cardiovascular system. Many attempts have been initiated to design macromolecular gadolinium (Gd[III]) complexes as magnetic resonance imaging blood-pool contrast agents, as macromolecules do not readily diffuse across healthy vascular endothelium, and remain intravascular. Although extremely efficacious in detecting and characterizing pathologic tissue, clinical development of these agents has been limited by potential toxicity concerns from incomplete Gd(III) clearance. Recent innovative technologies, such as reversible protein-binding contrast agents and biodegradable macromolecular contrast agents, may be valuable alternatives that combine the effective imaging characteristics of an intravascular contrast agent and the safety of clinically approved low-molecular-weight Gd(III) chelates.

PMID:: 17335412; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

Review

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Molecular Biology Databases

GADOLINIUM, ELEMENTAL - HSDB

Libraries

LinkOut Holdings

Supplemental Content

Save items

Related citations in PubMed

Review Polydisulfide Gd(III) chelates as biodegradable macromolecular magnetic resonance imaging contrast agents. [Int J Nanomedicine. 2006]
Review Polydisulfide Gd(III) chelates as biodegradable macromolecular magnetic resonance imaging contrast agents.
Lu ZR, Mohs AM, Zong Y, Feng Y. Int J Nanomedicine. 2006; 1(1):31-40.
Extracellular biodegradable macromolecular gadolinium(III) complexes for MRI. [Magn Reson Med. 2004]
Extracellular biodegradable macromolecular gadolinium(III) complexes for MRI.
Lu ZR, Parker DL, Goodrich KC, Wang X, Dalle JG, Buswell HR. Magn Reson Med. 2004 Jan; 51(1):27-34.
Gd-DTPA L-cystine bisamide copolymers as novel biodegradable macromolecular contrast agents for MR blood pool imaging. [Pharm Res. 2006]
Gd-DTPA L-cystine bisamide copolymers as novel biodegradable macromolecular contrast agents for MR blood pool imaging.
Kaneshiro TL, Ke T, Jeong EK, Parker DL, Lu ZR. Pharm Res. 2006 Jun; 23(6):1285-94. Epub 2006 Jun 1.
Structural effect on degradability and in vivo contrast enhancement of polydisulfide Gd(III) complexes as biodegradable macromolecular MRI contrast agents. [Magn Reson Imaging. 2009]
Structural effect on degradability and in vivo contrast enhancement of polydisulfide Gd(III) complexes as biodegradable macromolecular MRI contrast agents.
Zong Y, Wang X, Jeong EK, Parker DL, Lu ZR. Magn Reson Imaging. 2009 May; 27(4):503-11. Epub 2008 Sep 23.
Review Functional magnetic resonance imaging of the kidney using macromolecular contrast agents. [Abdom Imaging. 2006]
Review Functional magnetic resonance imaging of the kidney using macromolecular contrast agents.
Choyke PL, Kobayashi H. Abdom Imaging. 2006 Mar-Apr; 31(2):224-31.

See reviews... See all...

Cited by 8 PubMed Central articles

Protein polymer MRI contrast agents: Longitudinal analysis of biomaterials in vivo. [Magn Reson Med. 2011]
Protein polymer MRI contrast agents: Longitudinal analysis of biomaterials in vivo.
Karfeld-Sulzer LS, Waters EA, Kohlmeir EK, Kissler H, Zhang X, Kaufman DB, Barron AE, Meade TJ. Magn Reson Med. 2011 Jan; 65(1):220-8.
An effective targeted nanoglobular manganese(II) chelate conjugate for magnetic resonance molecular imaging of tumor extracellular matrix. [Mol Pharm. 2010]
An effective targeted nanoglobular manganese(II) chelate conjugate for magnetic resonance molecular imaging of tumor extracellular matrix.
Tan M, Wu X, Jeong EK, Chen Q, Parker DL, Lu ZR. Mol Pharm. 2010 Aug 2; 7(4):936-43.
Molecular imaging without radiopharmaceuticals? [J Nucl Med. 2009]
Molecular imaging without radiopharmaceuticals?
Gore JC, Yankeelov TE, Peterson TE, Avison MJ. J Nucl Med. 2009 Jun; 50(6):999-1007. Epub 2009 May 14.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.
Cited in Books
NCBI Bookshelf books that cite the current articles.

Recent activity

Clear Turn Off Turn On

Gadolinium(III)-based blood-pool contrast agents for magnetic resonance imaging:...
Gadolinium(III)-based blood-pool contrast agents for magnetic resonance imaging: status and clinical potential.
Expert Opin Drug Deliv. 2007 Mar ;4(2):149-64.

PubMed
The strong correlation of cytotoxic T lymphocyte-specific serine protease gene t...
The strong correlation of cytotoxic T lymphocyte-specific serine protease gene transcripts with renal allograft rejection.
Transplantation. 1992 Jan ;53(1):73-9.

PubMed
Nonsteroidal anti-inflammatory drugs and the risk of developing breast cancer in...
Nonsteroidal anti-inflammatory drugs and the risk of developing breast cancer in a population-based prospective cohort study in Washington County, MD.
Int J Cancer. 2007 Jul 1 ;121(1):211-15.

PubMed
Breast masses. Mammographic and sonographic evaluation.
Breast masses. Mammographic and sonographic evaluation.
Radiol Clin North Am. 1992 Jan ;30(1):67-92.

PubMed
Triple-negative breast cancer: therapeutic options.
Triple-negative breast cancer: therapeutic options.
Lancet Oncol. 2007 Mar ;8(3):235-44.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: